Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis.
Systemic onset juvenile rheumatoid arthritis (JRA) accounts for 10-15% of all JRA. Macrophage activation syndrome (MAS), which can also be considered as secondary hemophagocytic lymphohistiocytosis, is a potentially life-threatening complication of systemic onset JRA. We describe a child with systemic onset JRA who developed MAS after initiation of etanercept therapy.
Ramanan
Athimalaipet V
AV
Division of Pediatric Rheumatology, Hospital for Sick Children and Department of Pediatrics, University of Toronto, Ontario, Canada.
Schneider
Rayfel
R
D000799:Angioedema / Q000139:chemically induced / Q000276:immunology; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001171:Arthritis, Juvenile / Q000188:drug therapy* / Q000276:immunology*; D002675:Child, Preschool; D000068800:Etanercept; D005260:Female; D015616:Histiocytosis, Non-Langerhans-Cell / Q000139:chemically induced* / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000009:adverse effects*; D008262:Macrophage Activation / Q000187:drug effects*; D008264:Macrophages / Q000187:drug effects / Q000276:immunology; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept